What Caragen does

Caragen is an Ireland-based pharmaceutical and medical device distribution company headquartered in Sandyford, Dublin 18, founded in 2016. It operates as a full-service outsourcing solution provider, serving as the distribution bridge between international pharmaceutical/medical device manufacturers and Irish acute care hospitals — specifically hospital pharmacists, technicians, consultants, clinical nurse specialists, and procurement experts. The company addresses market complexity, supply chain disruptions, and poorly served therapeutic segments by providing end-to-end supply chain coverage from sourcing and qualification through procurement, marketing, sales, and distribution.

Caragen's commercial portfolio spans three product categories. First, automated pharmacy compounding systems sourced from its strategic partner Kiro Grifols: KIRO Oncology (robotic compounding for hazardous oncology drugs with gravimetric measurement, barcode readers, real-time cameras, dual peristaltic pumps, and an enclosed self-cleaning environment), KIRO Fill (automated non-hazardous sterile preparation with barcode/RFID identification, gravimetric control, and ISO 5 aseptic environment), and KIRO Link (web-based pharmacy management platform with bidirectional HL7 interfacing to Hospital Information Systems). Second, therapeutic proteins from human plasma distributed in partnership with Grifols, including Flebogamma DIF, Prolastin, Gamunex 10%, and the PediGri online traceability portal. Third, safety-oriented medical devices including oncology closed system transfer devices, needle-free drug delivery devices, and iAluRil. The company maintains ISO 13485:2016 certification and EU Medical Device Regulation compliance for its distribution activities.

Caragen generates revenue through B2B transaction-fee-based distribution of these products to Irish acute care hospitals, with quote-based pricing via hospital procurement systems. In February 2026, Caragen was acquired by UK specialty generics company Aspire Pharma Limited, gaining Irish distribution rights to over 100 product lines spanning immunology, oncology, infectious diseases, and medical devices. Post-acquisition, Caragen continues operating as an independent brand in Ireland with its existing management team, while gaining access to Aspire's broader European footprint for geographic expansion.

Name

Caragen

Legal name

Caragen Limited

Website

https://www.caragen.com

Company type

Private

Founded year

2016

Operating status

Acquired

Headcount range

1–10 employees

Short description

Caragen is a Dublin-based pharmaceutical distributor that sources and supplies therapeutic proteins, pharmaceuticals, medical devices, and Kiro Grifols automated pharmacy compounding systems to Irish acute care hospitals, operating as a B2B full-service outsourcing solution provider since 2016.

Ownership category

akta.pro rank

Headquarters

HQ city

Dublin

HQ country

Ireland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Distribution: Caragen generates revenue through sourcing, distributing, and supplying branded and generic pharmaceuticals, therapeutic proteins from human plasma, and medical devices to acute care hospitals. They operate as a full-service outsourcing solution provider for the pharmaceutical and medical device industry.
2. Distribution Rights Acquisition: Following Aspire Pharma's acquisition, Caragen distributes Irish rights to over 100 product lines spanning immunology, oncology, infectious diseases, and medical devices acquired through the transaction.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Caragen sources, supplies, and distributes therapeutic proteins from human plasma, branded and generic pharmaceuticals, and acute-care medical devices to Irish hospitals. As the exclusive Irish distributor for Kiro Grifols, it also provides automated pharmacy compounding systems (KIRO Oncology, KIRO Fill) and the KIRO Link pharmacy management platform, enabling end-to-end supply chain solutions from sourcing through procurement, marketing, sales, and distribution.

Product overview

Caragen is a Dublin-based pharmaceutical distribution company operating as a full-service outsourcing solution provider for the pharmaceutical, medical device, and healthcare industry. The company offers a diversified portfolio of products across three main categories: (1) Automated pharmacy systems including KIRO Oncology (robotic oncology compounding), KIRO Fill (automated sterile non-hazardous preparation), and KIRO Link (pharmacy management platform with HIS integration); (2) Therapeutic proteins from human plasma including Flebogamma DIF, Prolastin, Gamunex 10%, and PediGri portal; and (3) Medical devices including oncology closed system transfer devices, needle-free drug delivery devices, and iAluRil. Caragen serves as the bridge between pharmaceutical manufacturers and healthcare professionals in the acute care sector, providing end-to-end supply chain solutions from sourcing through distribution.

Differentiator

Problem solved

Functional benefit

Products and services

• KIRO Oncology

Quantifiable outcome

• 80% of all prescriptions dispensed in Ireland were filled with a generic drug in 2023, representing significant market opportunity for generic distributors
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Aspire PharmacoreStrategic or Co-development Partner · 1 February 2026Aspire Pharma Limited, a UK specialty generics company, acquired Caragen in February 2026. The acquisition strengthens Aspire's European footprint and grants access to Irish distribution rights for over 100 product lines. Caragen will continue operating as an independent brand in Ireland with its existing management team remaining in place.
• Kiro GrifolscoreTechnology or IntegrationStrategic partnership with Kiro Grifols, a leader in automated pharmaceutical preparation, to offer advanced technologies including KIRO Oncology (automated oncology compounding), KIRO Fill (automated sterile preparation), and KIRO Link (pharmacy management integration platform). These systems help hospitals reduce risk, enhance traceability, and ensure reliable medicine preparation.
• GrifolscoreTechnology or IntegrationPartnership with Grifols for distribution of therapeutic proteins from human plasma including Flebogamma DIF, Prolastin, Gamunex 10%, and PediGri online access portal. Grifols has been a key player in introducing innovative plasma therapies in Ireland and worldwide.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Others

• ICU Medical: US-headquartered manufacturer of IV therapy equipment, closed system transfer devices (CSTDs), and needle-free drug delivery connectors. Supplies the medical device categories (CSTDs, needle-free devices) that Caragen distributes to Irish acute care hospitals.
• Grifols: Global manufacturer of plasma-derived therapeutic proteins including Flebogamma DIF, Prolastin, and Gamunex 10%. Upstream supplier partner providing the biological products Caragen distributes to Irish hospitals via its PediGri portal and plasma franchise.

Direct peers

• Alloga UK: UK pre-wholesale pharmaceutical distribution services provider (part of Phoenix Group) operating warehousing and distribution for pharmaceutical manufacturers into hospitals and pharmacies. Comparable outsourced distribution model serving UK/Ireland hospital supply chains.
• Mawdsleys: UK-based pharmaceutical distribution and supply chain services company offering pre-wholesale, specialty, and licensed medicines distribution to hospitals, pharmacies, and manufacturers. Mirrors Caragen's specialty pharma distribution model and procurement-side outsourcing.
• Clinigen: Global pharmaceutical services company specializing in unlicensed, orphan, and specialty medicine supply, clinical trial supply, and hospital distribution. Highly comparable to Caragen's hard-to-source, poorly-served segment focus in therapeutic proteins and oncology.
• United Drug: Ireland's largest pharmaceutical wholesaler (part of Phoenix Group), distributing branded, generic, and specialty pharmaceuticals to pharmacies and hospitals across Ireland. Directly competes with Caragen for Irish hospital pharma distribution contracts and represents the most head-to-head comparable in market overlap.

Broad incumbents

• Phoenix Group: Pan-European pharmaceutical distribution group operating across multiple countries through subsidiaries including United Drug and Alloga. Operates the same wholesale distribution category as Caragen at substantially larger scale across European geographies.
• Alliance Healthcare: UK pharmaceutical wholesaler and distributor (part of Walgreens Boots Alliance) supplying branded, generic, and specialty medicines to pharmacies and hospitals across the UK and Ireland. Larger, broader-portfolio incumbent operating in the same hospital pharmaceutical distribution space.
• Aspire Pharma: UK specialty generics pharmaceutical company that acquired Caragen in February 2026, focused on niche and hard-to-source generic medicines across immunology and specialty therapy areas. Direct strategic overlap in product focus; now also parent, providing vertical insight into Caragen's positioning.
• Cencora: Global pharmaceutical distribution services and consulting company (formerly AmerisourceBergen) with European operations including specialty distribution and manufacturer services. Larger established incumbent in the same pharmaceutical distribution services category.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/about

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Caragen